Company Filing History:
Years Active: 2023
Title: Innovations of Paul M. Park in Protein Degradation
Introduction
Paul M. Park is a notable inventor based in Waltham, MA (US), recognized for his contributions to the field of protein degradation. He holds two patents that focus on innovative compounds designed to induce selective protein degradation, which has significant implications for treating various diseases.
Latest Patents
His latest patents include "Small molecules for inducing selective protein degradation and uses thereof." This patent describes bifunctional compounds that bind to target proteins and induce their ubiquitination for degradation. The compounds specifically target bromodomain-containing proteins and histone methyltransferases, promoting their degradation by recruiting them to the ubiquitin receptor RPN13 for proteasomal degradation. Additionally, the patent outlines pharmaceutical compositions that utilize these compounds for treating diseases such as cancers and inflammatory conditions.
Another significant patent is "DOT1L degraders and uses thereof." This invention involves bifunctional compounds that bind to an E3 ubiquitin ligase and the target protein DOT1L, facilitating its degradation. The patent also includes methods for treating proliferative diseases, particularly cancers, by administering these innovative compounds.
Career Highlights
Paul M. Park is currently affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance research in the field of cancer treatment through innovative approaches to protein degradation. His work is pivotal in developing new therapeutic strategies that target specific proteins involved in disease progression.
Collaborations
He collaborates with esteemed colleagues such as Jun Qi and Scott A. Armstrong, contributing to a dynamic research environment focused on cancer biology and therapeutic innovations.
Conclusion
Paul M. Park's innovative work in the field of protein degradation exemplifies the potential of targeted therapies in treating complex diseases. His patents reflect a commitment to advancing medical science and improving patient outcomes through groundbreaking research.